Literature DB >> 15166465

Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie.

Jérôme Solassol1, Carole Crozet1, Véronique Perrier1, Julien Leclaire2, Florence Béranger1, Anne-Marie Caminade2, Bernard Meunier2, Dominique Dormont3, Jean-Pierre Majoral2, Sylvain Lehmann4,1.   

Abstract

Over the last 30 years, many drugs have been tested both in cell culture and in vivo for their ability to prevent the generation of prions and the development of transmissible spongiform encephalopathies. Among the compounds tested, dendrimers are defined by their branched and repeating molecular structure. The anti-prion activity of new cationic phosphorus-containing dendrimers (P-dendrimers) with tertiary amine end-groups was tested. These molecules had a strong anti-prion activity, decreasing both PrP(Sc) and infectivity in scrapie-infected cells at non-cytotoxic doses. They can bind PrP and decrease the amount of pre-existing PrP(Sc) from several prion strains, including the BSE strain. More importantly, when tested in a murine scrapie model, the dendrimers were able to decrease PrP(Sc) accumulation in the spleen by more than 80 %. These molecules have a high bio-availability and therefore exhibit relevant potential for prion therapeutics for at least post-exposure prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166465     DOI: 10.1099/vir.0.19726-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

1.  Neutral high-generation phosphorus dendrimers inhibit macrophage-mediated inflammatory response in vitro and in vivo.

Authors:  I Posadas; L Romero-Castillo; N El Brahmi; D Manzanares; S Mignani; J-P Majoral; V Ceña
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

Review 2.  Therapeutic development of polymers for prion disease.

Authors:  Kenta Teruya; Katsumi Doh-Ura
Journal:  Cell Tissue Res       Date:  2022-03-21       Impact factor: 5.249

Review 3.  Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine.

Authors:  Xiang Li; Abid Naeem; Shanghua Xiao; Lei Hu; Jing Zhang; Qin Zheng
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525

Review 4.  Complex polyamines: unique prion disaggregating compounds.

Authors:  Surachai Supattapone; Justin R Piro; Judy R Rees
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

Review 5.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

6.  Nanomedicine for prion disease treatment: new insights into the role of dendrimers.

Authors:  James M McCarthy; Dietmar Appelhans; Jörg Tatzelt; Mark S Rogers
Journal:  Prion       Date:  2013 May-Jun       Impact factor: 3.931

7.  A cell-biased effect of estrogen in prion infection.

Authors:  Brendan Molloy; Hilary E M McMahon
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

8.  Interaction of Cationic Carbosilane Dendrimers and Their siRNA Complexes with MCF-7 Cells.

Authors:  Kamila Białkowska; Katarzyna Miłowska; Sylwia Michlewska; Paulina Sokołowska; Piotr Komorowski; Tania Lozano-Cruz; Rafael Gomez-Ramirez; Francisco Javier de la Mata; Maria Bryszewska
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

Review 9.  First-in-Class Phosphorus Dendritic Framework, a Wide Surface Functional Group Palette Bringing Noteworthy Anti-Cancer and Anti-Tuberculosis Activities: What Lessons to Learn?

Authors:  Serge Mignani; Jérôme Bignon; Xiangyang Shi; Jean-Pierre Majoral
Journal:  Molecules       Date:  2021-06-17       Impact factor: 4.411

10.  Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc).

Authors:  James M McCarthy; Markus Franke; Ulrike K Resenberger; Sibeal Waldron; Jeremy C Simpson; Jörg Tatzelt; Dietmar Appelhans; Mark S Rogers
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.